Nathanael Gray, Professor, Dana Farber Cancer Institute, Harvard Medical School To Give a Featured Presentation at the 3rd Protein Kinases & Drug Design
Online PR News – 07-July-2014 – Nathanael Gray, Professor, Biological Chemistry and Molecular Pharmacology, Dana Farber Cancer Institute, Harvard Medical School To Give a Featured Presentation on, New Approaches for Targeting Kinases with Covalent and Non-covalent Inhibitors at the 3rd Protein Kinases & Drug Design Conference (October 23-24, 2014 in Boston, MA) by GTCbio.
Kinases, key drivers of malignant transformation and major contributors to a variety of other human pathologies, have emerged as some of the most exciting targets in drug discovery. However, with initial well-documented success stories came realization that many hurdles lie in the path of successful development of new drugs, targeting kinase signaling.
Please help us out :
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
GTCbios 3rd Protein Kinases & Drug Design Conference, to be held in October 23-24, 2014, Boston, MA, will bring together speakers representing world-leading academic centers and pharmaceutical companies to discuss how to overcome the many hurdles and answer exciting key questions. Experts will also share their positive and negative experiences on how predictive preclinical models are with clinical efficacy and toxicology.
Sessions for 2014 Agenda:
This conference is part of our Protein Discovery Summit 2014, which consists of this and three additional parallel conferences shown below:
For more information, please visit www.gtcbio.com